Live

Save-the-Date: Livestream: MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further…

Tailoring Patient Care Using Novel Agents in Metastatic Urothelial Carcinoma: Strategies for the Interprofessional Team

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will…

Save the Date: MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further…

Emerging Considerations for the Role of Biomarker-Driven Immunotherapy in Upper GI Cancers

Upper gastrointestinal (GI) cancers are often undetected until late stages, leading to a poor prognosis. Treatment may be delayed or inappropriately assigned due to a lack of robust biomarker testing. To optimize patient outcomes, oncology clinicians…